

**Dr.T.S.Srinath Kumar**  
**Sr. Consultant, Head and Group Coordinator,**  
**Narayana Hrudayalaya Ltd., Bangalore**  
**Recepient – Distinguished PG Teacher DNB Emergency Medicine**

## IN HOSPITAL TREATMENT OF ARDS & STEROIDS IN SEPSIS





**Menderes Hazır ▶ ATUDER Acil  
Görüntüleme**


Sunday at 1:01 PM · 🌐

**ATUDER Başkanı Prof. Dr. Başar CANDER, Başkan Yardımcısı Prof. Zeynep ÇAKIR ve Genel Sekreterimiz Prof. Behçet AL 20th Annual Conference of Society for Emergency Medicine India ( SEMI )'nin Kongresinde — with Zeynep Gökcan Çakır and 2 others.**


See Translation



Arif Karagoz and 12 others



## Incidence of SEPSIS during 2018-19



# History

- The first description in 1967,
- Ashbaugh and colleagues described 12 patients
  - acute respiratory distress,
  - cyanosis refractory to oxygen therapy,
  - decreased lung compliance, and
  - diffuse infiltrates evident on the chest radiograph.
- 1988, an expanded definition was proposed that quantified the physiologic respiratory impairment through the use of a four-point lung-injury scoring system

**Table 2** Calculation of the lung injury score<sup>4</sup>

	Score
Chest radiograph	
No alveolar consolidation	0
Alveolar consolidation confined to 1 quadrant	1
Alveolar consolidation confined to 2 quadrants	2
Alveolar consolidation confined to 3 quadrants	3
Alveolar consolidation confined to 4 quadrants	4
Hypoxaemia score	
$\text{PaO}_2/\text{FiO}_2 \geq 300$	0
$\text{PaO}_2/\text{FiO}_2$ 225–299	1
$\text{PaO}_2/\text{FiO}_2$ 175–224	2
$\text{PaO}_2/\text{FiO}_2$ 100–174	3
$\text{PaO}_2/\text{FiO}_2 < 100$	4
PEEP score (when mechanically ventilated)	
$\leq 5$ cm $\text{H}_2\text{O}$	0
6–8 cm $\text{H}_2\text{O}$	1
9–11 cm $\text{H}_2\text{O}$	2
12–14 cm $\text{H}_2\text{O}$	3
$\geq 15$ cm $\text{H}_2\text{O}$	4
Respiratory system compliance score (when available)	
$\geq 80$ ml/cm $\text{H}_2\text{O}$	0
60–79 ml/cm $\text{H}_2\text{O}$	1
40–59 ml/cm $\text{H}_2\text{O}$	2
20–39 ml/cm $\text{H}_2\text{O}$	3
$\leq 19$ ml/cm $\text{H}_2\text{O}$	4
The score is calculated by adding the sum of each component and dividing by the number of components used.	
No lung injury	0
Mild to moderate lung injury	0.1–2.5
Severe lung injury (ARDS)	$>2.5$



Table 2: The Lung Injury Prediction Score

Predisposing conditions	LIPS Score	Examples
Shock	2	<p>(1) Patient with history of alcohol abuse with septic shock from pneumonia requiring <math>\text{FIO}_2 &gt; 0.35</math>  Emergency room: sepsis + shock + pneumonia + alcohol abuse + <math>\text{FIO}_2 &gt; 0.35</math>  <math>1 + 2 + 1.5 + 1 + 2 = 7.5</math></p> <p>(2) Motor vehicle accident with traumatic brain injury, lung contusion, and shock requiring <math>\text{FIO}_2 &gt; 0.35</math>  Traumatic brain injury + lung contusion + shock + <math>\text{FIO}_2 &gt; 0.35</math>  <math>2 + 1.5 + 2 + 2 = 7.5</math></p> <p>(3) Patient with history of diabetes mellitus and urosepsis with shock sepsis + shock + diabetes  <math>1 + 2 - 1 = 2</math></p>
Aspiration	2	
Sepsis	1	
Pneumonia	1.5	
High-risk surgery*		
Orthopaedic spine	1	
Acute abdomen	2	
Cardiac	2.5	
Aortic vascular	3.5	
High-risk trauma		
Traumatic brain injury	2	
Smoke inhalation	2	
Near drowning	2	
Lung contusion	1.5	
Multiple fractures	1.5	
Risk modifiers		
Alcohol abuse	1	
Obesity (BMI>30)	1	
Hypoalbuminemia	1	
Chemotherapy	1	
$\text{FIO}_2 > 0.35$ (>4 L/min)	2	
Tachypnoea (RR > 30)	1.5	
$\text{SpO}_2 < 95\%$	1	
Acidosis (pH < 7.35)	1.5	
Diabetes mellitus**	-1	

BMI = body mass index; RR = respiratory rate;  $\text{SpO}_2$  = oxygen saturation by pulse oximetry

\*Add 1.5 points in case of emergency surgery

\*\*Only in cases of sepsis

# Berlin definition

<b>Timing</b>	Within 1 week of a known clinical insult or new/worsening respiratory symptom
<b>Chest imaging</b>	Bilateral opacities – not fully explained by effusions, lobar/lung collapse, or nodules
<b>Origin of oedema</b>	Respiratory failure not fully explained by cardiac failure or fluid overload; need objective assessment (for example, a echocardiography) to exclude hydrostatic oedema if no risk factor present
<b>Oxygenation</b>	
<b>Mild</b>	$200 < \text{PaO}_2 / \text{FiO}_2 \leq 300$ , with PEEP $\geq 5$ cmH <sub>2</sub> O
<b>Moderate</b>	$100 < \text{PaO}_2 / \text{FiO}_2 \leq 200$ , with PEEP $\geq 5$ cmH <sub>2</sub> O
<b>Severe</b>	$\text{PaO}_2 / \text{FiO}_2 \leq 100$ , with PEEP $\geq 5$ cmH <sub>2</sub> O

# Etiology

## Direct causes

- **Common causes**
  - Pneumonia
  - Aspiration of gastric contents
- **Less common causes**
  - Pulmonary contusion
  - Fat emboli
  - Near-drowning
  - Inhalational injury
  - Reperfusion pulmonary edema
  - after lung transplantation or a pulmonary embolectomy

## Indirect causes

- **Common causes**
  - Sepsis
  - Severe trauma with shock and multiple transfusions
- **Less common causes**
  - Cardiopulmonary bypass
  - Drug overdose
  - Acute pancreatitis
  - Transfusions of blood products



P. Pelosi  
L. Gattinoni


## **Acute respiratory distress syndrome of pulmonary and extra-pulmonary origin: fancy or reality?**

- Difference explained interms of
  - Pathophysiology
  - Respiratory mechanics
  - Ventillatory strategies
  - Effect of prone positioning


# Pathophysiology

- **Endothelial and Epithelial Injury**
- Injury → Increased permeability → Influx of protein-rich edema fluid → hypoxemia
- Alveolar epithelium injury
- Neutrophils and other pro inflammatory – cytokines are involved

## Normal Alveolus



## Injured Alveolus during the Acute Phase



# Pathophysiology

- Refractory hypoxemia
  - Alveolar fluid → physiological shunt
  - Scattered microthrombi → increase dead space
  - Pulmonary hypertension → hypoxic/thrombotic
- Decrease lung compliance
  - Increase surface tension
  - Alveolar oedema
  - Baby lung
- Propensity for alveolar closure

# Ventilator associated lung injury

- Ventilation at High Lung Volumes(Volutrauma)
  - leading to alveolar rupture,
  - Air leaks
  - gross barotrauma
  - volume (i.e., lung stretching), not airway pressure, most important factor
- Ventilation at Low Lung Volumes(Atlectrauma)
  - Repetitive opening and closing of airways and lung units,
  - Effects on surfactant function,
  - regional hypoxia.
  - Epithelial sloughing, hyaline membranes



## A Ventilation at low lung volume

End expiration



End inspiration



Atelectrauma



Lung inhomogeneity

## B Ventilation at high lung volume

Normal



Hyperinflation




Air leaks



Overdistention

## C Structural consequences



**Ventilator-Induced Lung Injury**, Arthur S. Slutsky, M.D., and V. Marco Ranieri, M.D.,  
*N Engl J Med* 2013;369:2126-36



**Biologic alterations**

Increased concentrations of:  
Hydroxyproline  
Transforming growth factor- $\beta$   
Interleukin-8

Release of mediators:  
Tumor necrosis factor  $\alpha$  (TNF- $\alpha$ )  
 $\beta$ -catenin  
Interleukin-6 (IL-6)  
Interleukin-1 $\beta$  (IL-1 $\beta$ )

Recruitment of:  
Pulmonary alveolar macrophages (PAMs)  
Neutrophils

Activation of epithelium and endothelium

**Physiological abnormalities**

Increased physiological dead space

Decreased compliance

Decreased  $P_{aO_2}$   
Increased  $P_{aCO_2}$


**Systemic effects**

Translocation of:  
Lipopolysaccharides (LPS)  
Bacteria  
Various mediators

Multiple mechanisms  
(e.g., increased apoptosis)

Multiorgan  
dysfunction

Death




# Transpulmonary pressure and plateau pressure

- Transpulmonary pressure: principal force maintaining inflation  
(alveolar pressure minus pleural pressure)
- Measurement of pleural pressure is complicated & cumbersome
  - Estimated by esophageal pressure- yields only approximate results
- Plateau pressure as surrogate marker of lung over distension
- Nuances required in interpreting plateau pressure

**A** Normal spontaneously breathing person, at end inspiration

$P_{\text{alv}} = 0 \text{ cm H}_2\text{O}$



$P_{\text{pl}} = -8 \text{ cm H}_2\text{O}$

$$P_{\text{tp}} = 0 - (-8) = +8 \text{ cm H}_2\text{O}$$

**B** Normal anesthetized, paralyzed patient on mechanical ventilation, at end inspiration

$P_{\text{alv}} = 9 \text{ cm H}_2\text{O}$



$P_{\text{pl}} = 1 \text{ cm H}_2\text{O}$

$$P_{\text{tp}} = 9 - 1 = +8 \text{ cm H}_2\text{O}$$

**C** Patient with stiff chest wall, on mechanical ventilation, at end inspiration

$P_{\text{alv}} = 30 \text{ cm H}_2\text{O}$




$P_{\text{pl}} = 25 \text{ cm H}_2\text{O}$

$$P_{\text{tp}} = 30 - 25 = +5 \text{ cm H}_2\text{O}$$

**D** Trumpet player while playing a note

$P_{\text{alv}} = 150 \text{ cm H}_2\text{O}$




$P_{\text{pl}} = 140 \text{ cm H}_2\text{O}$

$$P_{\text{tp}} = 150 - 140 = +10 \text{ cm H}_2\text{O}$$

**E** Patient with marked respiratory distress, on noninvasive ventilation, at end inspiration

$P_{\text{alv}} = 10 \text{ cm H}_2\text{O}$




$P_{\text{pl}} = -15 \text{ cm H}_2\text{O}$

$$P_{\text{tp}} = 10 - (-15) = +25 \text{ cm H}_2\text{O}$$

# Baby lung concept

## Earlier concept


- ARDS involves all the lung tissue homogeneously
- ARDS lungs were regarded as homogeneously heavy and stiff
- To achieve normal  $\text{PaCO}_2$  high tidal volume ventilation was used
- To achieve normal  $\text{PaO}_2$  PEEP was employed




# Baby lung

- CT findings in ARDS in mid 1980
- ARDS appears non-homogeneous on CT, with the densities concentrated primarily in the most dependent regions
  - normally aerated,
  - poorly aerated,
  - overinflated, and nonaerated tissue
- Normally aerated tissue only forms a fraction of the whole lung- **Baby lung**





# Stages of ARDS



# Management of ARDS- Ventilation

- Calculate predicted Body weight
  - Male  $50 + 2.3(\text{height in inches} - 60)$
  - Females  $45.5 + 2.3(\text{height in inches} - 60)$
- Select any ventilator mode
- Set initial ventilator settings to achieve  $V_T$  8ml/kg
- Reduce  $V_T$  by 1 ml/kg at intervals  $\leq 2$  hours until  $V_T = 6\text{ml/kg}$
- Set initial rate to approximate baseline minute ventilation (not  $> 35$  bpm)
- Adjust  $V_T$  and RR to achieve pH and plateau pressure goals below



VENTILATION WITH LOWER TIDAL VOLUMES AS COMPARED WITH  
TRADITIONAL TIDAL VOLUMES FOR ACUTE LUNG INJURY  
AND THE ACUTE RESPIRATORY DISTRESS SYNDROME

THE ACUTE RESPIRATORY DISTRESS SYNDROME NETWORK\*

- RCT comparing  $V_T$  of 6ml/kg and 12ml/kg
- 861 patients were enrolled
- Mortality in low  $V_T$  31% as compared to 39.8% in control
- Ventilator free days were more in study group

# Setting up of PEEP

Start with initial PEEP of atleast 5 and target SPO2 of 88-95%

## Lower PEEP/higher FiO<sub>2</sub>

<b>FiO<sub>2</sub></b>	0.3	0.4	0.4	0.5	0.5	0.6	0.7	0.7
<b>PEEP</b>	5	5	8	8	10	10	10	12

<b>FiO<sub>2</sub></b>	0.7	0.8	0.9	0.9	0.9	1.0
<b>PEEP</b>	14	14	14	16	18	18-24

## Higher PEEP/lower FiO<sub>2</sub>

<b>FiO<sub>2</sub></b>	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.5
<b>PEEP</b>	5	8	10	12	14	14	16	16

<b>FiO<sub>2</sub></b>	0.5	0.5-0.8	0.8	0.9	1.0	1.0
<b>PEEP</b>	18	20	22	22	22	24



# *The* NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

JULY 22, 2004

VOL. 351 NO. 4

## Higher versus Lower Positive End-Expiratory Pressures in Patients with the Acute Respiratory Distress Syndrome

The National Heart, Lung, and Blood Institute ARDS Clinical Trials Network\*

### **Positive End-Expiratory Pressure Setting in Adults With Acute Lung Injury and Acute Respiratory Distress Syndrome** A Randomized Controlled Trial

Alain Mercat, MD

**Context** The need for lung protection is universally accepted, but the optimal level

### **Ventilation Strategy Using Low Tidal Volumes, Recruitment Maneuvers, and High Positive End-Expiratory Pressure for Acute Lung Injury and Acute Respiratory Distress Syndrome** A Randomized Controlled Trial

Maureen O. Meade, MD, MSc

**Context** Low-tilde-volume ventilation reduces mortality in critically ill patients with



# Higher vs Lower Positive End-Expiratory Pressure in Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome

## Systematic Review and Meta-analysis

---

- Meta analysis of 3 trials(ALVEOLI, LOVS, EXPRESS)
- Mortality benefit seen in patients with ARDS
- Patients with acute lung injury may not benefit or may actually experience harm from higher PEEP levels
- Small increase in risk of pneumothorax

**PLATEAU PRESSURE GOAL:  $\leq 30$  cm H<sub>2</sub>O**

Check Pplat (0.5 second inspiratory pause), at least q 4h and after each change in PEEP or V<sub>T</sub>.

**If Pplat > 30 cm H<sub>2</sub>O:** decrease V<sub>T</sub> by 1ml/kg steps (minimum = 4 ml/kg).

**If Pplat < 25 cm H<sub>2</sub>O and V<sub>T</sub> < 6 ml/kg,** increase V<sub>T</sub> by 1 ml/kg until Pplat > 25 cm H<sub>2</sub>O or V<sub>T</sub> = 6 ml/kg.

**If Pplat < 30 and breath stacking or dys-synchrony occurs:** may increase V<sub>T</sub> in 1ml/kg increments to 7 or 8 ml/kg if Pplat remains  $\leq 30$  cm H<sub>2</sub>O.

---

**pH GOAL: 7.30-7.45****Acidosis Management: (pH < 7.30)**

**If pH 7.15-7.30:** Increase RR until pH > 7.30 or PaCO<sub>2</sub> < 25 (Maximum set RR = 35).

**If pH < 7.15:** Increase RR to 35.

If pH remains < 7.15, V<sub>T</sub> may be increased in 1 ml/kg steps until pH > 7.15 (Pplat target of 30 may be exceeded).

May give NaHCO<sub>3</sub>

**Alkalosis Management: (pH > 7.45)** Decrease vent rate if possible.


---

# Role of recruitment maneuvers

- Clinical studies of RMs in ALI/ARDS have yielded variable results
- Factors such as the
  - Duration and
  - Underlying etiology of ARDS
  - Methods of the RM (e.g., sustained inflation versus incremental positive end-expiratory pressure [PEEP])
- may be important determinants of the potential for alveolar recruitment
- Optimal pressure, duration, and frequency of RMs have not been determined or tested in large clinical trials.


- Transient increase in oxygenation
- No effect on PEEP values or  $\text{FiO}_2$  concentration
- No mortality benefit
- May be used when
  - After suctioning
  - Disconnections
  - At initial stage before setting optimal PEEP
  - Rescue maneuver

Sustained Inflation



45%

Incremental PEEP



23%

Pressure Controlled Ventilation



20%

Time (min)

# Disadvantages


- 3 randomized, controlled trials were not able to demonstrate a beneficial effect of RMs on oxygenation in routine practice
- Some safety concerns
- Large variability of oxygenation response across the patients.
- Relevant end-points in assessment of RMs have moved from oxygenation improvement toward VILI prevention.
- Not recommended for routine practice



# Prone Ventilation

- Prone positioning, first proposed in 1974
- “Sponge model” of lung.
- Increase in oxygenation and improved lung mechanics
- CT scan shows a more homogeneous distribution of gas throughout lung parenchyma in prone ventilation
- In experimental models of ARDS, there is evidence that prone positioning prevents or significantly delays development of VILI.

# Physiology



- More tissue of lung in dorsal side for ventilation
- Shifting of heart weight
- Decrease effect of intraabdominal pressure

# *The* NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

JUNE 6, 2013

VOL. 368 NO. 23

## Prone Positioning in Severe Acute Respiratory Distress Syndrome

- Prone position given for atleast 16hrs
- 28 day mortality in prone group was 16% compared to 32% in supine
- No difference in adverse events b/w groups
- Participating hospitals had adequate experience to prone patients before study

RESEARCH

Open Access

# The effect of prone positioning on mortality in patients with acute respiratory distress syndrome: a meta-analysis of randomized controlled trials

Shu Ling Hu, Hong Li He, Chun Pan, Ai Ran Liu, Song Qiao Liu, Ling Liu, Ying Zi Huang, Feng Mei Guo, Yi Yang and Hai Bo Qiu\*

- Meta analysis of 9 RCT
- Decrease in mortality (28days, 60 days and 90 days) in prone position
- Prone position has to be done  $\geq 12$ hrs

# HFOV

- Ventilator strategy – small VT @1ml/kg at high frequencies  
10-15hz
- Gas is actively pushed in and actively withdrawn
- Vt less than dead space
- Rescue measure when conventional ventilation fail



# Mechanism of gas exchange


## Bulk convection

More gas is entrained into the alveoli by the vacuum left when oxygen is absorbed into the capillaries



## Pendelluft

Gas is exchanged between lung units which have different compliance and therefore different time constants



For any given plateau pressure

Alveolus open due to good compliance

Alveolus collapsing due to poor compliance


### Taylor dispersion

Gas is exchanged between the central rapid jet of oxygenated gas, and the relatively oxygen-poor gas at the periphery of airways.

The force behind this central jet allows it to penetrate deeper into the bronchial tree, allowing oxygenation of distal units

### Coaxial flow

A bi-directional flow of gas exists, with a central rapidly moving inspiratory column and a slower moving peripheral expiratory sleeve, pushed out of the lung by the force of the incoming gas.



# Values to be set in HFOV

- Mean airway pressure
- FiO<sub>2</sub>
- Amplitude or Delta P
- % inspiration
- Frequency

# *The* NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

FEBRUARY 28, 2013

VOL. 368 NO. 9

## High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome

### CONCLUSIONS

In adults with moderate-to-severe ARDS, early application of HFOV, as compared with a ventilation strategy of low tidal volume and high positive end-expiratory pressure, does not reduce, and may increase, in-hospital mortality. (Funded by the Canadian Institutes of Health Research; Current Controlled Trials numbers, ISRCTN42992782 and ISRCTN87124254, and ClinicalTrials.gov numbers, NCT00474656 and NCT01506401.)

*The* NEW ENGLAND JOURNAL *of* MEDICINE

### ORIGINAL ARTICLE

## High-Frequency Oscillation for Acute Respiratory Distress Syndrome


Duncan Young, D.M., Sarah E. Lamb, D.Phil., Sanjoy Shah, M.D.,  
Iain MacKenzie, M.D., William Tunnicliffe, M.Sc., Ranjit Lall, Ph.D.,

### CONCLUSIONS

The use of HFOV had no significant effect on 30-day mortality in patients undergoing mechanical ventilation for ARDS. (Funded by the National Institute for Health Research Health Technology Assessment Programme; OSCAR Current Controlled Trials number, ISRCTN10416500.)

# Role of ECMO

- Donald Hill and colleagues described the first use of an ECMO device for acute respiratory failure in humans
- They reported on a 24-year-old polytrauma patient
- The National Institutes of Health (NIH) performed the first multicenter trial in the 1970s,
- 90 patients with severe ARDS refractory to conventional ventilation
- 42 received ECMO.
- Survival was extremely low ( $<10\%$ )



In our Hospital we had 6 adult patients on ECMO in 2018 for ARDS – 50% was the results.



Health News / Latest Health News / Industry

Industry Narayana Health mechanical ventilation Karnataka Intensive Care Unit Carbon dioxide

# Karnataka: Mobile ECMO retrieval team of Narayana Health City saves a life

*Acute respiratory syndrome (ARDS) is a life-threatening lung condition wherein the flow of oxygen into the lungs and blood is prevented.*

ANI | March 29, 2019, 10:22 IST

Share Tweet

Print A A Newsletter



Bengaluru: Compassion has no boundaries and that's what happened with Nagesh. He was given a new lease of life at a city hospital by the ECMO (Extra Corporeal Life Support) retrieval

Subscribe To ETHealthworld Newsletter

125000+ Industry Leaders read it everyday

Your Email

Join Now!



# Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial



*Giles J Peek, Miranda Mugford, Ravindranath Tiruvoipati, Andrew Wilson, Elizabeth Allen, Mariamma M Thalanany, Clare L Hibbert, Ann Truesdale, Felicity Clemens, Nicola Cooper, Richard K Firmin, Diana Elbourne, for the CESAR trial collaboration*

- 63% (57/90) of patients allocated to consideration for treatment by ECMO survived to 6 months without disability compared with 47%
- Pitfalls
  - 22 patients randomized to the ECMO arm did not receive ECMO
  - No standardized protocol for lung-protective mechanical ventilation existed in the control group
  - Third, more patients received corticosteroids in the ECMO group

# Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome

The Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators\*

**Context** The novel influenza A(H1N1) pandemic affected Australia and New Zealand during the 2009 southern hemisphere winter. It caused an epidemic of critical illness and some patients developed severe acute respiratory distress syndrome (ARDS) and were treated with extracorporeal membrane oxygenation (ECMO).

**Conclusions** During June to August 2009 in Australia and New Zealand, the ICUs at regional referral centers provided mechanical ventilation for many patients with 2009 influenza A(H1N1)—associated respiratory failure, one-third of whom received ECMO. These ECMO-treated patients were often young adults with severe hypoxemia and had a 21% mortality rate at the end of the study period.

JAMA. 2009;302(17):1888-1895

[www.jama.com](http://www.jama.com)

- 63 patients kept on ECMO compared with 133 on mechanical ventilation
- Patients were younger, low apache score on admission in ECMO group

## **PART II: WEANING**

### **A. Conduct a SPONTANEOUS BREATHING TRIAL daily when:**

1.  $\text{FiO}_2 \leq 0.40$  and  $\text{PEEP} \leq 8$  OR  $\text{FiO}_2 \leq 0.50$  and  $\text{PEEP} \leq 5$ .
2.  $\text{PEEP}$  and  $\text{FiO}_2 \leq$  values of previous day.
3. Patient has acceptable spontaneous breathing efforts. (May decrease vent rate by 50% for 5 minutes to detect effort.)
4. Systolic BP  $\geq 90$  mmHg without vasopressor support.
5. No neuromuscular blocking agents or blockade.

### **B. SPONTANEOUS BREATHING TRIAL (SBT):**

**If all above criteria are met and subject has been in the study for at least 12 hours, initiate a trial of UP TO 120 minutes of spontaneous breathing with  $\text{FiO}_2 \leq 0.5$  and  $\text{PEEP} \leq 5$ :**

1. Place on T-piece, trach collar, or CPAP  $\leq 5$  cm H<sub>2</sub>O with PS  $\leq 5$
2. Assess for tolerance as below for up to two hours.
  - a.  $\text{SpO}_2 \geq 90$ : and/or  $\text{PaO}_2 \geq 60$  mmHg
  - b. Spontaneous  $\text{V}_T \geq 4$  ml/kg PBW
  - c.  $\text{RR} \leq 35/\text{min}$
  - d.  $\text{pH} \geq 7.3$
  - e. No respiratory distress (distress= 2 or more)
    - HR  $> 120\%$  of baseline
    - Marked accessory muscle use
    - Abdominal paradox
    - Diaphoresis
    - Marked dyspnea
3. If tolerated for at least 30 minutes, consider extubation.
4. If not tolerated resume pre-weaning settings.

# Non ventilatory strategies for ARDS- Fluid balance

- Adequate fluid resuscitation to treat the initial shock
- Once patient is out of shock conservative fluid strategy
- No mortality benefit but reduced on ventilation, no organ failure

*The NEW ENGLAND JOURNAL of MEDICINE*

ORIGINAL ARTICLE

## Comparison of Two Fluid-Management Strategies in Acute Lung Injury

The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network\*



# NMB in ARDS

- Early use of NMB in severe ARDS
  - Reduces mortality
  - Increased ventilator free days
  - No residual muscle weakness

*The* NEW ENGLAND  
JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

SEPTEMBER 16, 2010

VOL. 363 NO. 12

Neuromuscular Blockers in Early Acute Respiratory  
Distress Syndrome



# Steroids in ARDS

- Role of steroid is controversial
- Points to note
  - When to start
  - Dose
  - When to stop complications
  - Contraindications

# *The* NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

APRIL 20, 2006

VOL. 354 NO. 16

## Efficacy and Safety of Corticosteroids for Persistent Acute Respiratory Distress Syndrome

The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network\*

- Steroid started after 7 days
- No mortality benefit in steroid group
- Increase complications when started after 14 days
- Mortality benefit when started b/w 7-14days



# Glucocorticoid Treatment in Acute Lung Injury and Acute Respiratory Distress Syndrome

Paul E. Marik, MD<sup>a,\*</sup>, G. Umberto Meduri, MD<sup>b</sup>,  
Patricia R.M. ROCCO, MD, PhD<sup>c</sup>, Djillali Annane, MD, PhD<sup>d</sup>

**Table 2**  
Prolonged glucocorticoid treatment initiated before day 14 of acute lung injury/acute respiratory distress syndrome

Study	Hospital Mortality <sup>a</sup>	Reduction in Inflammation	Improvement in PAO <sub>2</sub> :FIO <sub>2</sub>	Reduction in Duration of MV	Reduction in ICU stay	Rate of Infection
<b>Early ALI/ARDS (≤3 d)</b>	38% vs 62%	3 of 3	4 of 4	4 of 4	3 of 3	.30 vs .39
Confalonieri et al, <sup>51</sup> 2005 (n = 46)	0.0% vs 30% <sup>b</sup>	Yes	Yes	Yes	Yes	0 vs .17
Lee et al, <sup>50</sup> 2005 (n = 20)	8% vs 88% <sup>b</sup>	NR	Yes	Yes	Yes	.33 vs 0
Annane et al, <sup>53</sup> 2006 <sup>c</sup> (n = 177)	64% vs 73% <sup>c</sup>	Yes	Yes	Yes	NR	14 vs .13
Meduri et al, <sup>16</sup> 2007 (n = 91)	24% vs 43% <sup>b</sup>	Yes	Yes	Yes	Yes	.63 vs 1.43
<b>Unresolving ARDS (≥5 d)</b>	26% vs 45%	5 of 5	5 of 5	2 of 3	2 of 3	.48 vs .51
Meduri et al, <sup>6</sup> 1998 (n = 22)	13% vs 57% <sup>b</sup>	Yes	Yes	Yes	Yes	0 vs NR
Varpula et al, <sup>56</sup> 2000 (n = 31)	19% vs 20% (30 days)	Yes	Yes	No	No	.56 vs .33
Huh et al, <sup>54</sup> 2002 (n = 48)	43% vs 74% <sup>b</sup>	Yes	Yes	NR	NR	NR
Steinberg et al, <sup>15</sup> 2006 (n = 132)	27% vs 36% (60 days)	Yes	Yes	Yes	Yes	.31 vs .47
<b>Early and Unresolving ARDS</b>	34% vs 55%	8 of 8	9 of 9	6 of 7	5 of 6	.38 vs .44

- Meta analysis of 8 studies
- Shows definitive mortality benefit
- No higher risk of infection
- Dose 1-2mg/kg/day
- Most of the trials started steroids early
- Evidence regarding use in H1N1 controversial
- Not to be combined with other drugs causing neuromuscular weakness

# Source FICM – 2018 document

- Treatment Harms

Potential harms of treatment with steroids included excess hospital acquired infections, neuromyopathy and delirium. The only available MA reported a composite analysis of infection, neuromyopathy, diabetes, gastrointestinal bleeding and other complications<sup>21</sup>. The RR reported was 0.82 (0.5 to 1.36) but the quality of the trials was low.

- GRADE Recommendation Statement

The use of corticosteroids in established ARDS should be the subject of a suitably powered multicentre RCT with long term follow up, that focuses on both potential benefits and harms. (GRADE Recommendation: research recommendation).

# Nutrition

- Standard supportive care for the patient with ALI/ARDS includes providing adequate nutrition
- The enteral route is preferred to the parenteral route and is associated with fewer infectious complications
- Immunomodulation via dietary manipulation has been attempted, using various combinations of omega-3 fatty acids, ribonucleotides, arginine, and glutamine
- The ARDS Network -large, multicenter, randomized placebo-controlled study of omega-3 fatty acid and antioxidant supplementation in patients with ALI/ARDS. Study was stopped early for a trend towards excess mortality in patients receiving the omega-3 fatty acid supplement
- Overall, there is still no compelling evidence to support the use of anything other than standard enteral nutritional support, with avoidance of overfeeding, in ALI/ARDS



# Others

- Inhaled nitric oxide
  - Transiently improves oxygenation but does not improve mortality
  - Increase chance of renal dysfunction
- Prostaglandins
  - Inhaled prostaglandins improves oxygenation in small trials
  - Larger trials are awaited

- Where mechanical ventilation is required, the use of low tidal volumes ( $< 6$  ml/kg ideal body weight) and airway pressures (plateau pressure  $< 30$  cmH<sub>2</sub>O) was recommended. For patients with moderate/severe ARDS (PF ratio  $< 20$  kPa), prone positioning was recommended for at least 12 hours per day.
- high frequency oscillation is not recommended and it is suggested that inhaled nitric oxide is not used. The use of a conservative fluid management strategy was suggested for all patients, whereas mechanical ventilation with high positive end-expiratory pressure (PEEP) and the use of the neuro-muscular blocking agent cisatracurium for 48 hours was suggested for ARDS patients with PF ratios less than or equal to 27 and 20 kPa respectively.

**Our Vision – Strengthening skills  
will strengthen the Nation**

**Each one Teach one  
...Save Lives**

**Thank you!**

